Medicines in Development 2022 Report: Disorders of the Blood
PhRMA
5/18/2022 1:00:00 AM
Share This
Today, there are more than 500 medicines in development for disorders of the blood. A new report from PhRMA explores these medicines that target these diseases and conditions.
Interested in reading more about Medicines in Development for Blood Disorders in 2022?
Justine Dell’Aringa is director of Translational Medicine at Bristol Myers Squibb (BMS) where she leads a team of researchers at the organization's Immuno-Oncology and Cell Therapy Thematic Research Center.
Teri Foy, Ph.D, is the Senior Vice President of Research and Early Development. She oversees a team of researchers working tirelessly on translating scientific advances in immune effector cell-based therapies into treatments for hematological and solid cancers.
Blood disorders often require lifelong treatment involving routine drug infusions or blood transfusions. They can also be associated with frequent visits to physician offices, infusion centers or even the emergency room.